<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-title>Lipids in Health and Disease</journal-title><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1476-511X-8-17</article-id><article-id pub-id-type="pmid">19476644</article-id><article-id pub-id-type="doi">10.1186/1476-511X-8-17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Is adiponectin associated with acute myocardial infarction in Iranian non obese patients?</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Shojaie</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>shojaie1300@yahoo.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Sotoodah</surname><given-names>Abdoreza</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>sotoodehj2002@yahoo.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Shafaie</surname><given-names>Ghafar</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Best_mind1379@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Cardiology Department, Jahrom Medical University, Jahrom, Iran</aff><aff id="I2"><label>2</label>Immunology Department, Jahrom Medical University, Jahrom, Iran</aff><aff id="I3"><label>3</label>Peymanieh Hospital, Jahrom Medical University, Jahrom, Iran</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>28</day><month>5</month><year>2009</year></pub-date><volume>8</volume><fpage>17</fpage><lpage>17</lpage><ext-link ext-link-type="uri" xlink:href="http://www.lipidworld.com/content/8/1/17"/><history><date date-type="received"><day>15</day><month>2</month><year>2009</year></date><date date-type="accepted"><day>28</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Shojaie et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Shojaie et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Shojaie Mohammad shojaie1300@yahoo.com </dc:author><dc:title> Is adiponectin associated with acute myocardial infarction in Iranian non obese patients? </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Lipids in Health and Disease 8(1): 17-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-511X(2009)8:1&#x0003c;17&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-511X</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Backgrounds</title><p>Adiponectin is an adipose tissue-derived mediator with significant anti-atherogenic properties. A few studies were done in acute phase of myocardial infarction especially in non obese patients. We design a study to investigate the association between adiponectin concentration and acute phase of myocardial infarction in non obese patients.</p></sec><sec sec-type="methods"><title>Methods</title><p>This case-control study was done in Paymaneah Hospital (Jahrom, Iran) from Feb 2007 to May 2008. Plasma adiponectin levels were measured in 43 patients with AMI (mean age: 62.7 &#x000b1; 13.3 years, male: 67.4%) at the first 24 hours of admission and 43 normal controls (mean age: 62.1 &#x000b1; 12.3 years, male: 55.8%) matched for age, sex and other CAD risk factors.</p></sec><sec><title>Results</title><p>Adiponectin levels in patients with AMI (3.36 &#x003bc;g/mL) were significantly lower than that of the control group (5.03 &#x003bc;g/mL) (p &#x0003c; 0.0001). Lower adiponectin were independently associated with higher risk of AMI (odds ratio = 8.97; 95% CIs: 2.3&#x02013;34.5; p = 0.001). Adiponectin levels negatively correlated with triglyceride (r = -0.46, p = 0.002) and total cholesterol (r = -0.32, p = 0.03) in the case group and with body mass index (BMI) in control subjects.</p></sec><sec><title>Conclusion</title><p>The present study showed that adiponectin was associated with AMI in non obese patients but it is not related to sex, age and other CAD risk factors.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Adiponectin is a new member of adipocyte derived proteins belonging to the soluble defense collagens that produces specifically by adipose tissue and is present in the circulation [<xref ref-type="bibr" rid="B1">1</xref>]. Lower levels of plasma adiponectin have been detected in obesity [<xref ref-type="bibr" rid="B1">1</xref>], Type 2 diabetes mellitus [<xref ref-type="bibr" rid="B2">2</xref>] and coronary artery disease (CAD) [<xref ref-type="bibr" rid="B3">3</xref>]. Adiponectin appears to play an important role in glucose and lipid metabolism, vascular biology, and energy homeostasis [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>] and low adiponectin level has been shown as a risk factor for cardiovascular events [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Although several studies have been done on adiponectin and CAD, but most of them have been conducted on patients with chronic ischemia and the studies in acute phase of myocardial infarction (MI) especially in developing countries are limited and rare [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Yet there is controversy about the association of adiponectin and sex [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B11">11</xref>], CAD risk factors [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B14">14</xref>] and race [<xref ref-type="bibr" rid="B13">13</xref>]. Although adiponectin decreased in both obesity and AMI, some study [<xref ref-type="bibr" rid="B9">9</xref>] considered this for explanation of obesity effect on AMI, but with attention to direct effect of adiponectin on atherosclerosis [<xref ref-type="bibr" rid="B15">15</xref>], it seems that hypo adiponectinemia in AMI is independent of obesity.</p><p>The purpose of present study was to investigate the association between plasma adiponectin levels and AMI in Iranian non obese patients.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>This case-control study conducted on 43 consecutive patients with acute myocardial infarction (AMI) (as case group) including 29 men and 16 women with the mean age of 62.72 &#x000b1; 13.4 y/o out of 850 patients who were referred with chest pain to emergency room at Paymaneah Hospital, a referral center affiliated to Jahrom Medical University (Iran) from Feb 2007 to May 2008. We selected all patients after approved diagnosis of AMI and rule out of other patients with exclusion criteria. We also selected 43 individuals with atypical chest pain and normal coronary angiography as control group and matched them with case group for age, sex and other CAD risk factors such as hypertension (HTN), diabetes mellitus (DM), hyperlipidemia (HLP), body mass index (BMI), smoking and renal function.</p><p>The study protocol was approved by research ethics committee of Jahrom Medical University and informed consent was obtained from all participants before enrollment.</p><p>A questionnaire including information about the past medical and drug history (HTN, HLP, DM, smoking, chronic diseases such as rheumatologic disorder, renal failure and asthma), family history of CAD and demographic information was completed for each subjects.</p><p>The exclusion criteria were the history of infectious diseases, collagen vascular disease such as systemic lupus erythematous, scleroderma, rheumatoid arthritis, cirrhosis, hepatitis, renal disease, malignancy, septicemia, angioplasty and stable or unstable angina.</p></sec><sec><title>Definitions</title><p>AMI was defined as resting chest pain lasting more than 30 minutes accompanied by ischemic electrocardiographic changes and was confirmed by the presence of total creatine kinase or creatine kinase isoenzyme (CK-MB) fraction levels of more than twice the upper normal limit. We considered ST elevation MI (STEMI) according to ST segment elevation &#x0003e; 1 mm in two neighbor electrocardiographic leads and non ST elevation MI (NSTEMI) without this finding [<xref ref-type="bibr" rid="B16">16</xref>]. The absence of any narrowing in coronary artery diameter was considered as normal coronary angiography. Unstable angina was defined as angina pectoris (or equivalent type of ischemic discomfort) with at least one of three features: occurring at rest (or minimal exertion) and usually lasting &#x0003e; 20 minutes (if not interrupted by nitroglycerin administration); being severe and described as frank pain, and of new onset (i.e., within 1 month; and occurring with a crescendo pattern (i.e., more severe, prolonged, or frequent than previously) [<xref ref-type="bibr" rid="B17">17</xref>]. Height and weight were measured with light clothes and without shoes using a stadiometer and electronic scale in the cardiac care unit after confirming patient stable condition. Body mass index was calculated [weight (kg)/height (m)<sup>2</sup>] and used as the criteria of overall adiposity. We defined BMI less than 25 as normal, 26&#x02013;30 as overweight and above 30 as obese [<xref ref-type="bibr" rid="B18">18</xref>]. Blood pressure was measured two times in sitting position after 5 min of rest using a mercury sphygmomanometer (Riester, Germany). Hypertension was defined as blood pressure more than 130/85 mmHg or use of any antihypertensive medication [<xref ref-type="bibr" rid="B19">19</xref>]. Diabetes mellitus was defined by a physician's diagnosis, a fasting plasma glucose level of &#x02265; 126 mg/dl or use of diabetes medications [<xref ref-type="bibr" rid="B20">20</xref>]. All subjects completed a research questionnaire on smoking habits.</p></sec><sec><title>Laboratory analysis</title><p>Fasting levels of plasma total cholesterol, high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), and triglycerides were determined in Research Laboratory of Jahrom Medical University. Total cholesterol and triglyceride levels were measured by enzymatic techniques using an Selectra E biochromatic analyzer. HDL and LDL level was measured after precipitation of the other lipoproteins with heparin and manganese chloride (Human, Germany). Plasma glucose levels were measured by the glucose oxidase method and serum creatinine by the Jaffe reaction method.</p><p>Blood samples (5 cc) for adiponectin were obtained by venipuncture from the patients immediately after admission before starting any IV medication by trained staff and for lipid profile and fasting blood sugar at the first 24 hours of AMI after 12 hours of fasting. In control subjects all blood sample were obtained after 12 hours of fasting then plasma was separated and frozen at -70&#x000b0;C for later processing. Then we determined the plasma adiponectin concentration by enzyme linked immunosorbent assay (ELISA) (Biovendor Laboratory Medicine, Inc., Brno, Czech Republic) (<italic>REF: RD195023100</italic>) in patients and control group. This assay measures the total adiponectin that is all molecular forms. The sensitivity and the intra- and interassay coefficients of variation were 0.8 mg/liter, 6% and 7%, respectively.</p></sec><sec><title>Statistical analysis</title><p>Statistical analysis was performed by SPSS (version 11.5; SPSS, Inc., Chicago, IL). Data were expressed as mean &#x000b1; 1 SD. Continuous variables were summarized as mean &#x000b1; SD and compared using Student's <italic>t</italic>-test. Discrete variables were presented as frequencies and group percentages. Nominal variables were tested with Pearson's &#x003c7;<sup>2 </sup>test and Binary variables were tested with the Mann-whitney test. Pearson correlation coefficients were calculated to evaluate unadjusted (univariate) associations between adiponectin and other variables. All tests were two-tailed with a 0.05 type I error rate. Logistic regression models were used to estimate odds ratios (ORs) between three different adiponectin levels and AMI. We considered adiponectin level greater than 5 &#x003bc;g/ml as reference level.</p></sec></sec><sec><title>Results</title><p>The demographic and clinical characteristics of the study groups, as well as laboratory variables are shown in Table <xref ref-type="table" rid="T1">1</xref>. In patient group 6 cases (14%) had non-ST elevation MI (NSTEMI) and 37 (86%) had ST elevation MI (STEMI).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Variable</td><td align="center">Case group<break/> n = 43</td><td align="center">Control group<break/> n = 43</td><td align="center">P-value</td></tr></thead><tbody><tr><td align="center">Age</td><td align="center">62.7 &#x000b1; 13.3</td><td align="center">62.1 &#x000b1; 12.3</td><td align="center">0.84</td></tr><tr><td align="center">Male, n (%)</td><td align="center">29 (67.4%)</td><td align="center">24 (55.8%)</td><td align="center">0.27</td></tr><tr><td align="center">BMI (kg/m<sup>2</sup>)</td><td align="center">22.3 &#x000b1; 3</td><td align="center">23.6 &#x000b1; 3.15</td><td align="center">0.44</td></tr><tr><td align="center">Current smoker, n(%)</td><td align="center">10 (23.3%)</td><td align="center">4 (9.3%)</td><td align="center">0.14</td></tr><tr><td align="center">HTN, n(%)</td><td align="center">9 (20.9%)</td><td align="center">14 (32.6%)</td><td align="center">0.33</td></tr><tr><td align="center">Adiponectin (&#x003bc;g/mL)</td><td align="center">3.3 &#x000b1; 1.7</td><td align="center">5 &#x000b1; 1.5</td><td align="center">&#x0003c; 0.001*</td></tr><tr><td align="center">Type 1 DM, n (%)</td><td align="center">2 (4.7%)</td><td align="center">4(9.3%)</td><td align="center">0.68</td></tr><tr><td align="center">Type 2 DM, n (%)</td><td align="center">7(16.3%)</td><td align="center">4(9.3%)</td><td align="center">0.52</td></tr><tr><td align="center">Total Cholesterol (mg/dL)</td><td align="center">189.3 &#x000b1; 45.2</td><td align="center">171.8 &#x000b1; 33</td><td align="center">0.05</td></tr><tr><td align="center">LDL-C (mg/dL)</td><td align="center">113.7 &#x000b1; 36.6</td><td align="center">103.9 &#x000b1; 28.7</td><td align="center">0.13</td></tr><tr><td align="center">HDL-C (mg/dL)</td><td align="center">46.7 &#x000b1; 11.4</td><td align="center">41.9 &#x000b1; 9.5</td><td align="center">0.05</td></tr><tr><td align="center">LDL/HDL ratio</td><td align="center">4.23</td><td align="center">4.24</td><td align="center">0.96</td></tr><tr><td align="center">Triglyceride (mg/dL)</td><td align="center">146 &#x000b1; 99.6</td><td align="center">144 &#x000b1; 99.8</td><td align="center">0.93</td></tr><tr><td align="center">Serum creatinine (mg/dl)</td><td align="center">1 &#x000b1; 0.1</td><td align="center">1.1 &#x000b1; 0.1</td><td align="center">0.68</td></tr></tbody></table><table-wrap-foot><p>BMI: body mass index, LDL-C: low density lipoprotein- cholesterol, HDL-C: high density lipoprotein- cholesterol, BUN: blood urea nitrogen</p><p>Values are presented as mean &#x000b1; SD or %.</p></table-wrap-foot></table-wrap><p>Plasma adiponectin levels in the patients with AMI on admission were significantly lower than those in the control group (3.3 &#x000b1; 1.7 &#x003bc;g/ml vs. 5 &#x000b1; 1.5 &#x003bc;g/ml, p &#x0003c; 0.001).</p><p>We examined the association between plasma adiponectin levels and selected cardiovascular risk factors among cases and controls. There was a significant negative correlation between plasma adiponectin levels and triglyceride (r = -0.46, p = 0.002) and total cholesterol (r = -0.33, p = 0.03) in the case group as well as BMI in control group (r = -0.44, p = 0.003). No significant correlation was found between HTN, Type 1 DM, Type 2 DM, age, sex, smoking, serum creatinine, LDL and HDL and adiponectin levels (Table <xref ref-type="table" rid="T2">2</xref>). There was no significant difference in plasma adiponectin between patients with STEMI and NSTEMI (3.4 &#x000b1; 1.7 &#x003bc;g/ml vs. 3 &#x000b1; 1.5 &#x003bc;g/ml, p = 0.49).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Pearson Correlation Coefficients between Plasma Adiponectin Level and selected variables in the Case and Control groups</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Variable</bold></td><td align="center" colspan="2"><bold>Case group</bold></td><td align="center" colspan="2"><bold>Control group</bold></td></tr><tr><td></td><td align="center">Correlation</td><td align="center">P-value</td><td align="center">Correlation</td><td align="center">P-value</td></tr></thead><tbody><tr><td align="left">Age</td><td align="center">0.24</td><td align="center">0.04*</td><td align="center">0.04</td><td align="center">0.79</td></tr><tr><td align="left">BMI</td><td align="center">-0.03</td><td align="center">0.86</td><td align="center">-0.44</td><td align="center">0.003**</td></tr><tr><td align="left">Serum creatinine</td><td align="center">0.13</td><td align="center">0.41</td><td align="center">0.27</td><td align="center">0.08</td></tr><tr><td align="left">Total Cholesterol</td><td align="center">-0.33</td><td align="center">0.03*</td><td align="center">-0.11</td><td align="center">0.48</td></tr><tr><td align="left">LDL-C</td><td align="center">-0.03</td><td align="center">0.84</td><td align="center">-0.02</td><td align="center">0.87</td></tr><tr><td align="left">HDL-C</td><td align="center">-0.06</td><td align="center">0.72</td><td align="center">-0.09</td><td align="center">0.55</td></tr><tr><td align="left">Triglyceride</td><td align="center">-0.46</td><td align="center">0.002**</td><td align="center">-.09</td><td align="center">0.57</td></tr><tr><td align="left">TC/HDL</td><td align="center">-0.22</td><td align="center">0.14</td><td align="center">-0.40</td><td align="center">0.80</td></tr></tbody></table><table-wrap-foot><p>*P &#x0003c; 0.05, **P &#x0003c; 0.001</p><p>BMI: body mass index, IDDM: insulin dependent diabetes mellitus, NIDDM: non insulin dependent diabetes mellitus, LDL-C: low density lipoprotein- cholesterol, HDL-C: high density lipoprotein- cholesterol, BUN: blood urea nitrogen</p></table-wrap-foot></table-wrap><p>Patients were divided into three groups based on adiponectin split level. The results are shown in Table <xref ref-type="table" rid="T3">3</xref>. The group with the adiponectin levels greater than 80<sup>th </sup>percentile (5 &#x003bc;g/mL) was used as the reference. Odds ratio for AMI increased with decreasing adiponectin levels. Lower adiponectin were independently associated with higher risk of AMI (odds ratio = 8.97; 95% CIs: 2.3&#x02013;34.5; p = 0.001). The greatest increase in AMI risk was seen at adiponectin levels &#x02264; 3 &#x003bc;g/mL.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Odds ratio association of different adiponectin levels with acute myocardial infarction (AMI)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Adiponectin levels</td><td align="center">Case group (AMI) (n, %)</td><td align="center">Control group<break/><bold>(n,%)</bold></td><td align="center">P value</td><td align="center">OR (95% CI)</td></tr></thead><tbody><tr><td align="left"> &#x0003e; 5 &#x003bc;g/mL</td><td align="center">9 (20.9%)</td><td align="center">19 (44.2%)</td><td></td><td align="center">Reference group (1.00)</td></tr><tr><td align="left">3.01&#x02013;5 &#x003bc;g/mL</td><td align="center">17 (39.5.6%)</td><td align="center">20 (46.5%)</td><td align="center">0.26</td><td align="center">1.97 (0.65&#x02013;4.99)</td></tr><tr><td align="left">&#x02264; 3 &#x003bc;g/mL</td><td align="center">17 (39.5%)</td><td align="center">4(9.3%)</td><td align="center">0.001*</td><td align="center">8.97 (2.3&#x02013;34.5)</td></tr></tbody></table><table-wrap-foot><p>CI: Confidence Interval, OR: odds ratio</p><p>*p &#x0003c; 0.001 significant with single logistic regression analysis</p></table-wrap-foot></table-wrap></sec><sec><title>Discussion</title><p>In the present case-control study, in line with previous studies [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B21">21</xref>], we found that lower plasma adiponectin levels was associated with AMI among Iranian non obese patients independent of traditional cardiovascular risk factors. Of note, the relationship was also independent of hypertension, diabetes, age, sex, BMI and smoking; the factors that were closely related to adiponectin levels in previous studies [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Cavusoglu et al. [<xref ref-type="bibr" rid="B22">22</xref>] showed that high baseline plasma adiponectin levels are independently associated with an increased risk of both death and MI at 2-year follow-up in a cohort of men with stable angina, unstable angina, and non ST elevation MI referred for coronary angiography. Our study also showed significant association between adiponectin levels in patients with ST elevation MI and non-ST elevation MI in spite of their different pathophysiology [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. These findings indicated that adiponectin may be directly involved in the pathophysiology of atherosclerosis and thrombosis at the vascular wall level.</p><p>The exact mechanism of adiponectin decrease immediately after the onset of AMI remains unknown. Although some authors [<xref ref-type="bibr" rid="B25">25</xref>] believed that the changed adiponectin levels are associated with presence of risk factors of metabolic syndrome but our findings in line of other studies emphasis that its deficiency may lead to thrombus formation and platelet aggregation [<xref ref-type="bibr" rid="B15">15</xref>]. Plasma adiponectin may decrease as a result of rupture of coronary plaques. Adiponectin has been detected in the injured vessels but not in the intact ones in humans and rodents [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Although it seems that low adiponctin in AMI is secondary to plaque rupture and inflammation but if according to previous cohort studies [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B28">28</xref>] adiponectin consider as risk factor for coronary artery disease, measurement of adiponectin levels may be helpful in the stratification of patients at risk of AMI. In our study the greatest increase in MI risk occurred at adiponectin levels &#x02264; 3 &#x003bc;g/mL in contrast to the Wolk et al. study [<xref ref-type="bibr" rid="B9">9</xref>] that this rise occurred at adiponectin levels &#x02264; 5.5 &#x003bc;g/mL. This difference may be due to exclusion of the patients with major CAD risk factors in Wolk et al. study that were not excluded from us. Our present data, consistent with those of other authors [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B25">25</xref>] showed that adiponectin levels was negatively correlated with triglycerides in patients and with BMI only in the control subjects, but in contrast to the others we found negative correlation with total cholesterol in patients and any correlation with other CAD risk factors such as smoking[<xref ref-type="bibr" rid="B14">14</xref>], age, DM, HTN, HDL and LDL.</p><p>About non significant correlation between plasma adiponectin levels and BMI in case group, it should be noted that in the most of previous studies [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B29">29</xref>] there were significant but weak correlation (r = -0.18 to -0.33) between them, So, in confirming Pliz et al opinion [<xref ref-type="bibr" rid="B11">11</xref>], it should be noted that the adiponectin levels may be more associated with blood lipid profile and insulin resistance instead of obesity. Also this difference may be due to reduction of adiponectin secondary to acute MI.</p><p>Most studies [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B14">14</xref>] showed higher adiponectin levels in women in comparison to men but our results showed no statistically significant difference in adiponectin levels between men and women. Nakamura et al. [<xref ref-type="bibr" rid="B8">8</xref>] found similar results but they believed that solid phase ELISA was the reason for this difference, because this assay cannot distinguish between the lower weight trimer-dimer forms of adiponectin and the high molecular weight complexes; one of the factors associated with sex difference. We measured all forms of adiponectin and this difference in our study is not related to this reason. It may be due to less obesity in our subjects and/or mismatch between BMI in men and women in other studies.</p><p>Another remarkable clinical finding in our study was that plasma adiponectin levels in our study were much lower than those of other studies [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B14">14</xref>] such that this level in our normal subjects was approximately equal to that of patients with AMI. This may be due to lower BMI in our subjects, high carbohydrate diet [<xref ref-type="bibr" rid="B30">30</xref>] or race differences.</p><p>Kanaya et al. [<xref ref-type="bibr" rid="B13">13</xref>] showed that Whites had higher median adiponectin levels than Blacks and high circulating levels of adiponectin were associated with a higher risk of CAD in older Blacks. Significant differences in our results indicate that before application of adiponectin in clinical setting, further prospective and cohort studies in other countries and races are required to confirm our results.</p><p>Although some studies [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>] showed increased adiponectin level in patients with renal dysfunction but our study showed as the same of Shibata et al. [<xref ref-type="bibr" rid="B32">32</xref>] that there is no association between adiponectin and renal function in atherosclerotic patients with normal renal function.</p><sec><title>Study limitations</title><p>Serum adiponectin levels were measured in a single sample, which might limited the observed associations. Weak or any correlation may be due to small number of participants in this study. We didn't study the association of adiponectin concentration with amount of smoking, diet and previous medication because of limited data. Some authors such as Inoue et al. [<xref ref-type="bibr" rid="B33">33</xref>] suggest that measurement of high molecular weight (HMW) adiponectin alone may be a clinically useful marker of CAD but we measured only total form of adiponectin. Although abdominal obesity can give better insight than BMI, but because some studies use only BMI, for comparison we only used this parameter too.</p></sec></sec><sec><title>Conclusion</title><p>Lower plasma adiponectin levels are associated with AMI in Iranian non obese patients, independent of other traditional cardiovascular risk factors. Our findings showed although obesity is a reducing factor of adiponectin but this decreased in AMI is not related only to obesity.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>MS had substantial contributions to conception and design and interpretation of data and writing the manuscript. AS carried out the biochemical analysis. GS had contributions to data analysis. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study was supported by Vice Chancellor for Education and Research of the Jahrom Medical University.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Miyagawa</surname><given-names>J</given-names></name><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Miyaoka</surname><given-names>K</given-names></name><name><surname>Kuriyama</surname><given-names>H</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Okubo</surname><given-names>K</given-names></name><name><surname>Matsubara</surname><given-names>K</given-names></name><name><surname>Muraguchi</surname><given-names>M</given-names></name><name><surname>Ohmoto</surname><given-names>Y</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>257</volume><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">10092513</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1999.0255</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Iwahashi</surname><given-names>H</given-names></name><name><surname>Kuriyama</surname><given-names>H</given-names></name><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>N</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Muraguchi</surname><given-names>M</given-names></name><name><surname>Ohmoto</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Hanafusa</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2000</year><volume>20</volume><fpage>1595</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10845877</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Kuriyama</surname><given-names>H</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>2473</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10604883</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Havel</surname><given-names>PJ</given-names></name></person-group><article-title>Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>S143</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">14749280</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.53.2007.S143</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chandran</surname><given-names>M</given-names></name><name><surname>Phillips</surname><given-names>SA</given-names></name><name><surname>Ciaraldi</surname><given-names>T</given-names></name><name><surname>Henry</surname><given-names>RR</given-names></name></person-group><article-title>Adiponectin: more than just another fat cell hormone?</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>2442</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">12882876</pub-id><pub-id pub-id-type="doi">10.2337/diacare.26.8.2442</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Efstathiou</surname><given-names>SP</given-names></name><name><surname>Tsioulos</surname><given-names>DI</given-names></name><name><surname>Tsiakou</surname><given-names>AG</given-names></name><name><surname>Gratsias</surname><given-names>YE</given-names></name><name><surname>Pefanis</surname><given-names>AV</given-names></name><name><surname>Mountokalakis</surname><given-names>TD</given-names></name></person-group><article-title>Plasma adiponectin levels and five-year survival after first-ever ischemic stroke</article-title><source>Stroke</source><year>2005</year><volume>36</volume><fpage>1915</fpage><lpage>1919</lpage><pub-id pub-id-type="pmid">16109902</pub-id><pub-id pub-id-type="doi">10.1161/01.STR.0000177874.29849.f0</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pischon</surname><given-names>T</given-names></name><name><surname>Girman</surname><given-names>CJ</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name></person-group><article-title>Plasma adiponectin levels and risk of myocardial infarction in men</article-title><source>JAMA</source><year>2004</year><volume>291</volume><fpage>1730</fpage><lpage>1737</lpage><pub-id pub-id-type="pmid">15082700</pub-id><pub-id pub-id-type="doi">10.1001/jama.291.14.1730</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>D</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Ehara</surname><given-names>S</given-names></name><name><surname>Hirose</surname><given-names>M</given-names></name><name><surname>Kataoka</surname><given-names>T</given-names></name><name><surname>Kamimori</surname><given-names>K</given-names></name><name><surname>Shimodozono</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Yoshiyama</surname><given-names>M</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>J</given-names></name></person-group><article-title>Implications of plasma concentrations of adiponectin in patients with coronary artery disease</article-title><source>Heart</source><year>2004</year><volume>90</volume><fpage>528</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15084551</pub-id><pub-id pub-id-type="doi">10.1136/hrt.2003.011114</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolk</surname><given-names>R</given-names></name><name><surname>Berger</surname><given-names>P</given-names></name><name><surname>Lennon</surname><given-names>RJ</given-names></name><name><surname>Brilakis</surname><given-names>ES</given-names></name><name><surname>Davison</surname><given-names>DE</given-names></name><name><surname>Somers</surname><given-names>VK</given-names></name></person-group><article-title>Association between plasma adiponectin levels and unstable coronary syndromes</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><fpage>292</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">17090613</pub-id><pub-id pub-id-type="doi">10.1093/eurheartj/ehl361</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Soejima</surname><given-names>H</given-names></name><name><surname>Hokamaki</surname><given-names>J</given-names></name><name><surname>Kajiwara</surname><given-names>I</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Yoshimura</surname><given-names>M</given-names></name><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Miyao</surname><given-names>Y</given-names></name><name><surname>Suefuji</surname><given-names>H</given-names></name><name><surname>Kitagawa</surname><given-names>A</given-names></name><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name></person-group><article-title>The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction</article-title><source>Heart</source><year>2003</year><volume>89</volume><fpage>667</fpage><pub-id pub-id-type="pmid">12748233</pub-id><pub-id pub-id-type="doi">10.1136/heart.89.6.667</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pilz</surname><given-names>S</given-names></name><name><surname>Horejsi</surname><given-names>R</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>R</given-names></name><name><surname>Almer</surname><given-names>G</given-names></name><name><surname>Scharnagl</surname><given-names>H</given-names></name><name><surname>Stojakovic</surname><given-names>T</given-names></name><name><surname>Dimitrova</surname><given-names>R</given-names></name><name><surname>Weihrauch</surname><given-names>G</given-names></name><name><surname>Borkenstein</surname><given-names>M</given-names></name><name><surname>Maerz</surname><given-names>W</given-names></name><name><surname>Schauenstein</surname><given-names>K</given-names></name><name><surname>Mangge</surname><given-names>H</given-names></name></person-group><article-title>Early Atherosclerosis in Obese Juveniles Is Associated with Low Serum Levels of Adiponectin</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>4792</fpage><lpage>4796</lpage><pub-id pub-id-type="pmid">15928248</pub-id><pub-id pub-id-type="doi">10.1210/jc.2005-0167</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Otsuka</surname><given-names>F</given-names></name><name><surname>Maruyoshi</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name></person-group><article-title>Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction</article-title><source>Atherosclerosis</source><year>2006</year><volume>194</volume><fpage>204</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">16970953</pub-id><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2006.07.028</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanaya</surname><given-names>AM</given-names></name><name><surname>Wassel</surname><given-names>FC</given-names></name><name><surname>Vittinghoff</surname><given-names>E</given-names></name><name><surname>Havel</surname><given-names>PJ</given-names></name><name><surname>Cesari</surname><given-names>M</given-names></name></person-group><article-title>Serum adiponectin and coronary heart disease risk in older Black and White Americans</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>5044</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">16984981</pub-id><pub-id pub-id-type="doi">10.1210/jc.2006-0107</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laughlin</surname><given-names>GA</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>May</surname><given-names>S</given-names></name><name><surname>Langenberg</surname><given-names>C</given-names></name></person-group><article-title>Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study</article-title><source>Am J Epidemiol </source><year>2007</year><volume>165</volume><fpage>164</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">17101706</pub-id><pub-id pub-id-type="doi">10.1093/aje/kwk001</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Kashiwagi</surname><given-names>H</given-names></name><name><surname>Shiraga</surname><given-names>M</given-names></name><name><surname>Tadokoro</surname><given-names>S</given-names></name><name><surname>Kamae</surname><given-names>T</given-names></name><name><surname>Ujiie</surname><given-names>H</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><name><surname>Miyata</surname><given-names>S</given-names></name><name><surname>Ijiri</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>J</given-names></name><name><surname>Maeda</surname><given-names>N</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Kurata</surname><given-names>Y</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name><name><surname>Tomiyama</surname><given-names>Y</given-names></name><name><surname>Kanakura</surname><given-names>Y</given-names></name></person-group><article-title>Adiponectin acts as an endogenous antithrombotic factor</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2006</year><volume>26</volume><fpage>224</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">16269667</pub-id><pub-id pub-id-type="doi">10.1161/01.ATV.0000194076.84568.81</pub-id></citation></ref><ref id="B16"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Libby P, Bonow RO, Mann DL, Zipes DP</surname></name></person-group><article-title>ST-elevation Myocardial Infarction: pathology, pthophysiology and clinical feature</article-title><source>Braunwalds Heart Disease</source><year>2008</year><edition>8</edition><publisher-name>Elsevier Saunders company</publisher-name><fpage>1207</fpage></citation></ref><ref id="B17"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Libby P, Bonow RO, Mann DL, Zipes DP</surname></name></person-group><article-title>UnStable Angina and Non ST- elevation Myocardial Infarction</article-title><source>Braunwalds Heart Disease</source><year>2008</year><edition>8</edition><publisher-name>Elsevier Saunders company</publisher-name><fpage>1243</fpage></citation></ref><ref id="B18"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Flier</surname><given-names>JS</given-names></name><name><surname>Maratos-Flier</surname><given-names>E</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Fauci AS, Braunwald E, Kasper DL, Hause SL, Longo DL, et al</surname></name></person-group><article-title>Biology of obesity</article-title><source>Harrison's principle of internal medicine</source><year>2008</year><edition>17</edition><publisher-name>Mc Grow Hill company. Philadelphia: USA</publisher-name><fpage>262</fpage><lpage>3</lpage></citation></ref><ref id="B19"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Victor</surname><given-names>RG</given-names></name><name><surname>Kaplan</surname><given-names>NM</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Libby P, Bonow RO, Mann DL, Zipes DP</surname></name></person-group><article-title>Systemic Hypertension: Mechanisms and Diagnosis</article-title><source>Braunwalds Heart Disease</source><year>2008</year><edition>8</edition><publisher-name>Elsevier Saunders company</publisher-name><fpage>1027</fpage></citation></ref><ref id="B20"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>AC</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Fauci AS, Braunwald E, Kasper DL, Hause SL, Longo DL, et al</surname></name></person-group><article-title>Diabetes Mellitus</article-title><source>Harrison's principle of internal medicine</source><year>2008</year><edition>17</edition><publisher-name>Mc Grow Hill company. Philadelphia: USA</publisher-name><fpage>2275</fpage></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwashima</surname><given-names>Y</given-names></name><name><surname>Horio</surname><given-names>T</given-names></name><name><surname>Kumada</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Rakugi</surname><given-names>H</given-names></name><name><surname>Kawano</surname><given-names>Y</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name></person-group><article-title>Adiponectin and renal function, and implication as a risk of cardiovascular disease</article-title><source>Am J Cardiol</source><year>2006</year><volume>15; 98</volume><fpage>1603</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17145218</pub-id><pub-id pub-id-type="doi">10.1016/j.amjcard.2006.07.039</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavusoglu</surname><given-names>E</given-names></name><name><surname>Ruwende</surname><given-names>C</given-names></name><name><surname>Chopra</surname><given-names>V</given-names></name><name><surname>Yanamadala</surname><given-names>S</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Clark</surname><given-names>LT</given-names></name><name><surname>Pinsky</surname><given-names>DJ</given-names></name><name><surname>Marmur</surname><given-names>JD</given-names></name></person-group><article-title>Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><fpage>2300</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16864609</pub-id><pub-id pub-id-type="doi">10.1093/eurheartj/ehl153</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Un stable angina: An etiologic approach to management</article-title><source>Circulation</source><year>1998</year><volume>98</volume><fpage>2219</fpage><pub-id pub-id-type="pmid">9826306</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marrow</surname><given-names>DA</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Future of Biomarkers in acute coronary syndrome: Moving toward a multi marker strategy</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>250</fpage><pub-id pub-id-type="pmid">12876133</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000078080.37974.D2</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stejskal</surname><given-names>D</given-names></name><name><surname>Bartek</surname><given-names>J</given-names></name></person-group><article-title>Adiponectine in patients with various stages of coronary heart disease &#x02013; comparision of its concentration in coronary arteries and peripheral venous circulation</article-title><source>Biomed Papers</source><year>2003</year><volume>147</volume><fpage>161</fpage><lpage>166</lpage></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Matsuyama</surname><given-names>A</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Ishigami</surname><given-names>M</given-names></name><name><surname>Kuriyama</surname><given-names>H</given-names></name><name><surname>Kishida</surname><given-names>K</given-names></name><name><surname>Nishizawa</surname><given-names>H</given-names></name><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Muraguchi</surname><given-names>M</given-names></name><name><surname>Ohmoto</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages</article-title><source>Circulation</source><year>2001</year><volume>103</volume><fpage>1057</fpage><lpage>1063</lpage><pub-id pub-id-type="pmid">11222466</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okamaoto</surname><given-names>Y</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Muraguchi</surname><given-names>M</given-names></name><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Igura</surname><given-names>T</given-names></name><name><surname>Inui</surname><given-names>Y</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Miyagawa</surname><given-names>J</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls</article-title><source>Horm Metab Res</source><year>2000</year><volume>32</volume><fpage>47</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">10741683</pub-id><pub-id pub-id-type="doi">10.1055/s-2007-978586</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frystyl</surname><given-names>J</given-names></name><name><surname>Berne</surname><given-names>C</given-names></name><name><surname>Breglund</surname><given-names>L</given-names></name><name><surname>Jenesvik</surname><given-names>K</given-names></name><name><surname>Flyvbjerg</surname><given-names>A</given-names></name><name><surname>Zethelius</surname><given-names>B</given-names></name></person-group><article-title>Serum Adiponectin Is a Predictor of Coronary Heart Disease: A Population-Based 10-Year Follow-Up in Eldery Men</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>571</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">17119002</pub-id><pub-id pub-id-type="doi">10.1210/jc.2006-1067</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwashima</surname><given-names>Y</given-names></name><name><surname>Horio</surname><given-names>T</given-names></name><name><surname>Kumada</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Rakugi</surname><given-names>H</given-names></name><name><surname>Kawano</surname><given-names>Y</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name></person-group><article-title>Adiponectin and Renal Function, and Implication as a Risk of Cardiovascular Disease</article-title><source>Am J Cardiol</source><year>2006</year><volume>98</volume><fpage>1603</fpage><lpage>1608</lpage><pub-id pub-id-type="pmid">17145218</pub-id><pub-id pub-id-type="doi">10.1016/j.amjcard.2006.07.039</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pischon</surname><given-names>T</given-names></name><name><surname>Girman</surname><given-names>CJ</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name></person-group><article-title>Association between dietary factors and plasma adiponectin concentrations in men</article-title><source>Am J Clin Nutr</source><year>2005</year><volume>81</volume><fpage>780</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">15817852</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>O</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Kotoda</surname><given-names>A</given-names></name><name><surname>Akimoto</surname><given-names>T</given-names></name><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Muto</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>SE</given-names></name><name><surname>Kusano</surname><given-names>E</given-names></name></person-group><article-title>Serum adiponectin and markers of endothelial injury in hemodialysis patients with arteriosclerosis obliterans</article-title><source>Clin Exp Nephrol</source><year>2008</year><volume>12</volume><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">18175063</pub-id><pub-id pub-id-type="doi">10.1007/s10157-007-0012-7</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>R</given-names></name><name><surname>Numaguchi</surname><given-names>Y</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>Sone</surname><given-names>T</given-names></name><name><surname>Kubota</surname><given-names>R</given-names></name><name><surname>Ohashi</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Murohara</surname><given-names>T</given-names></name></person-group><article-title>Usefulness of Adiponectin to Predict Myocardial Salvage Following Successful Reperfusion in Patients With Acute Myocardial Infarction</article-title><source>Am J Cardiol</source><year>2008</year><volume>101</volume><fpage>1712</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18549845</pub-id><pub-id pub-id-type="doi">10.1016/j.amjcard.2008.02.057</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Kotooka</surname><given-names>N</given-names></name><name><surname>Morooka</surname><given-names>T</given-names></name><name><surname>Komoda</surname><given-names>H</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Aso</surname><given-names>Y</given-names></name><name><surname>Inukai</surname><given-names>T</given-names></name><name><surname>Okuno</surname><given-names>T</given-names></name><name><surname>Node</surname><given-names>K</given-names></name></person-group><article-title>High Molecular Weight Adiponectin as a Predictor of Long-Term Clinical Outcome in Patients with Coronary Artery Disease</article-title><source>Am J Cardiol</source><year>2007</year><volume>100</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">17697807</pub-id><pub-id pub-id-type="doi">10.1016/j.amjcard.2007.03.062</pub-id></citation></ref></ref-list></back></article> 